Literature DB >> 24562616

What causes decreased erythromycin resistance in Streptococcus pyogenes? Dynamics of four clones in a southern European region from 2005 to 2012.

Milagrosa Montes1, Esther Tamayo2, Catalina Mojica3, José M García-Arenzana3, Olatz Esnal2, Emilio Pérez-Trallero4.   

Abstract

OBJECTIVES: To survey antibiotic resistance among Streptococcus pyogenes isolates collected from 2005 to 2012, to characterize those showing erythromycin resistance and to analyse the association of certain emm types with erythromycin resistance or susceptibility.
METHODS: Resistance determinants or mutations conferring erythromycin, clindamycin, tetracycline and fluoroquinolone resistance were analysed. All erythromycin-resistant isolates and a sample of erythromycin-susceptible isolates were emm typed. Multilocus sequence typing was performed for representative emm types.
RESULTS: Antimicrobial susceptibility was studied for 12 346 S. pyogenes isolates. Erythromycin, clindamycin and tetracycline resistance showed a decreasing trend. In 2012, 2.8% of isolates were erythromycin resistant versus 7.5% in 2005 and 11.7% in 2006. Although 21 clones were involved, 4 clones accounted for almost 90% of erythromycin-resistant isolates. The emm12/ST36 clone, carrying the mef(A) gene, was the predominant (41.1%) erythromycin-resistant clone, with an incidence peak in 2008, followed by a gradual decline. The M phenotype predominated each year except for 2005, when two of the main erythromycin-resistant clones (emm11/ST403 and emm28/ST52) harboured an erm(B) gene. Erythromycin resistance was significantly higher in adults than in children. Skin isolates showed the highest erythromycin resistance rate; among these, perianal isolates frequently belonged to the emm28/ST52 clone. The emm type was not a predictor of erythromycin resistance; however, most emm11 and emm12 were erythromycin-resistant isolates. Macrolide consumption was similar throughout the study period. Only two isolates with a high level of levofloxacin resistance were detected.
CONCLUSIONS: Resistance was mainly related to the circulation of emm12/ST36, emm11/ST403, emm28/ST52 and emm4/ST39 clones, all of which declined throughout the study period.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  MLST; emm types; erm(B) gene; mef(A) gene; mutation A2058G

Mesh:

Substances:

Year:  2014        PMID: 24562616     DOI: 10.1093/jac/dku039

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Antibiotic Susceptibility Profiles and Frequency of Resistance Genes in Clinical Shiga Toxin-Producing Escherichia coli Isolates from Michigan over a 14-Year Period.

Authors:  Sanjana Mukherjee; Heather M Blankenship; Jose A Rodrigues; Rebekah E Mosci; James T Rudrik; Shannon D Manning
Journal:  Antimicrob Agents Chemother       Date:  2021-08-23       Impact factor: 5.191

2.  Decline in macrolide resistance rates among Streptococcus pyogenes causing pharyngitis in children isolated in Italy.

Authors:  G Gherardi; D Petrelli; M C Di Luca; F Pimentel de Araujo; P Bernaschi; A Repetto; J Bellesi; L A Vitali
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-05-30       Impact factor: 3.267

3.  Antimicrobial susceptibility patterns, emm type distribution and genetic diversity of Streptococcus pyogenes recovered in Brazil.

Authors:  Glauber P Arêas; Rôde B B Schuab; Felipe P G Neves; Rosana R Barros
Journal:  Mem Inst Oswaldo Cruz       Date:  2014-10-28       Impact factor: 2.743

4.  Optimal Diagnosis and Treatment of Group A Streptococcal Pharyngitis.

Authors:  Sunjoo Kim
Journal:  Infect Chemother       Date:  2015-09-30

5.  Emerging Threat of Antimicrobial Resistance in β-Hemolytic Streptococci.

Authors:  Oddvar Oppegaard; Steinar Skrede; Haima Mylvaganam; Bård Reiakvam Kittang
Journal:  Front Microbiol       Date:  2020-05-15       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.